
The FDA has concluded its investigation into Novartis and its data manipulation of the gene therapy Zolgensma, and has decided …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

